- All six directors were re-elected, with over 88% approval for most, but Ronald W. Miller received 68.75% approval.
- Deloitte LLP was appointed as COSCIENS Biopharma's (CSCI, Financial) auditor.
- Shareholders approved the Amended and Restated Shareholder Rights Plan.
COSCIENS Biopharma Inc. (CSCI), a life sciences company listed on NASDAQ and TSX, announced the results of its virtual Annual General and Special Meeting of Shareholders (AGSM) held on June 30, 2025. Key outcomes included the re-election of all six directors, with Peter H. Puccetti, Anthony J. Giovinazzo, Ulrich Kosciessa, Robert A. Seager, and David Spear receiving over 88% approval of votes. However, Ronald W. Miller was re-elected with a lower approval rating of 68.75%, with 31.25% of votes against.
Additionally, Deloitte LLP was appointed as the company's auditor, affirming their role in overseeing COSCIENS' financial practices. The shareholders also passed a resolution to confirm and approve the Amended and Restated Shareholder Rights Plan.
COSCIENS was exempted from certain Canadian requirements regarding its long-term incentive plan due to its status as an Eligible Interlisted Issuer on the TSX. This exemption eliminates the need for shareholder approval of unallocated entitlements at the AGSM.
COSCIENS continues to develop and commercialize a diverse portfolio of cosmeceutical, nutraceutical, and pharmaceutical products, leveraging proprietary extraction technology for producing active ingredients used in popular skincare brands and developing potential nutraceuticals and pharmaceuticals. The company remains committed to expanding its portfolio, strengthening its market position, and delivering value to shareholders.
